Bromocriptine
- Generic Name
- Bromocriptine
- Brand Names
- Cycloset, Parlodel
- Drug Type
- Small Molecule
- Chemical Formula
- C32H40BrN5O5
- CAS Number
- 25614-03-3
- Unique Ingredient Identifier
- 3A64E3G5ZO
- Background
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptin...
- Indication
For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodop...
- Associated Conditions
- Acromegaly, Hyperprolactinemia, Parkinson's Disease (PD), Type 2 Diabetes Mellitus, Neuroleptic malignant syndrome (NMS)
- Associated Therapies
- -
The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism
- Conditions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2007-03-23
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT00451672
- Locations
- 🇨🇳
National Taiwan Univserty Hospital, Taipei, Taiwan
Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- VeroScience
- Target Recruit Count
- 3095
- Registration Number
- NCT00377676
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 208
- Registration Number
- NCT00240409
- Locations
- 🇨🇳
First Hospital of Beijing University, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2010-10-06
- Target Recruit Count
- 40
- Registration Number
- NCT00004300
- Locations
- 🇺🇸
Western Carolina Center, Morganton, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.